Physician profile
Craig E Buckles
NPI 1487689527
$464.04
in general payments reported to CMS, 2019-2025
12 companies · $59.45 in 2025
The $59.45 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2023: $67.58 · 2024: $60.09 · 2025: $59.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $84.71 | 2023-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $83.50 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $64.83 | 2019-2025 | Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $39.07 | 2019 | |
| Neurocrine Biosciences, INC. | $30.66 | 2019 | |
| Indivior INC. | $30.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.77 | 2019 | |
| Avanir Pharmaceuticals, INC. | $25.40 | 2019 | |
| Shire North American Group INC | $24.75 | 2019 | |
| Vanda Pharmaceuticals INC. | $21.22 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.63 | 2024 | |
| Neos Therapeutics, LP | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Buckles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.